Drug Patent — Monthly Amortisation
Monthly amortisation of an approved drug's capitalised patent value over its remaining useful life.
| Account Name | Type | Debit ($) | Credit ($) |
|---|---|---|---|
| Amortisation Expense — Drug Patent | Expense (+) | 5,556,000.00 | - |
| Accumulated Amortisation — Drug Patent | Contra-Asset (+) | - | 5,556,000.00 |
💡 Accountant's Note
A drug patent acquired for USD 400M with 6 remaining years of exclusivity amortises at USD 5,556,000/month. Patent amortisation is a major non-cash expense for pharmaceutical companies with large acquired drug portfolios and drives the difference between GAAP net income and adjusted (non-GAAP) earnings commonly reported by pharma companies.
Practitioner & Systems Framework
💻 ERP Architecture
Drug patent amortisation is calculated automatically by the intangible asset module using the straight-line method over the configured useful life. The monthly amortisation journal is generated in batch. Patent amortisation is a significant bridge item in pharma companies' GAAP-to-adjusted EPS reconciliation — investors and analysts track 'core' or 'adjusted' earnings that exclude intangible amortisation from acquisitions. The amortisation schedule is disrupted if the drug is impaired, the patent is extended, or a generic/biosimilar launches earlier than anticipated (accelerating the remaining life amortisation).
⚠️ Audit Flags
Auditors test that the useful life assumption is still appropriate — any new generic entry, biosimilar approval, patent challenge, or pricing/access restriction may shorten the economic life. An accelerated amortisation adjustment or impairment is triggered if the remaining economic life is shorter than the accounting useful life. Confirm that any patent extensions (e.g., paediatric exclusivity, SPC — Supplementary Protection Certificate) are captured in the useful life. Test that the intangible is included in the annual impairment assessment.
📄 Required Documentation
Intangible asset register entry, amortisation schedule, useful life review (annual), generic/biosimilar entry risk assessment, patent extension documentation, competitive intelligence on market exclusivity, impairment testing results, and GAAP-to-adjusted EPS reconciliation.
Professional Excel Template
Get the automated version of this entry. Includes built-in IFRS checks, VAT calculators, and SAP-ready upload formats.
Expert Analysis by Qusai Ahmad
General Accountant Supervisor & IFRS Specialist
Specialized in SAP GUI automation and Middle Eastern tax compliance. Building digital tools for the next generation of finance leaders.